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Abstract
Multiple  myeloma  (MM)  is  associated  with  a  significant  risk  of  infection  due  to  immune 
dysfunction. Infections are a major cause of morbidity and mortality in MM patients. There 
are few data available regarding the prevalence of infection in MM patients, e
conjunction with newer generations of immunomodulatory drugs (thalidomide, bortezomib, 
lenalidomide)  or  post  autologous  stem  cell  transplantation  (ASCT).  Intravenous 
immunoglobulin  (IVIG)  has  been  used  successfully  to  reduce  infection  rates  in
phase of MM, with limited data in other stages. 
We  retrospectively  analyzed 47 patients with  MM  from March 2006  to June 2009  at our 
institution. All patients received thalidomide and steroid therapy for at least 6 months. Nine 
patients  received  bortezomib  and  11  lenalidomide  subsequent  to  thalidomide,  because  of 
disease progression, and 22 patients underwent ASCT.  The median age was 64 years (range 
37-86), with a female–to-male ratio of 18:29. The median residual
infection was 3.2 g/L, IgA 0.3 g/L and IgM 0.2 g/L. Most patients suffered from recurrent 
moderate to severe bacterial infections, including the ASCT group. Fifteen patients suffered 
from different degrees of viral infections. 
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Multiple  myeloma  (MM)  is  associated  with  a  significant  risk  of  infection  due  to  immune 
dysfunction. Infections are a major cause of morbidity and mortality in MM patients. There 
are few data available regarding the prevalence of infection in MM patients, e
conjunction with newer generations of immunomodulatory drugs (thalidomide, bortezomib, 
lenalidomide)  or  post  autologous  stem  cell  transplantation  (ASCT).  Intravenous 
immunoglobulin  (IVIG)  has  been  used  successfully  to  reduce  infection  rates  in
phase of MM, with limited data in other stages. 
We retrospectively analyzed 47  patients with  MM  from March 2006  to June 2009  at our 
institution. All patients received thalidomide and steroid therapy for at least 6 months. Nine 
d  bortezomib  and  11  lenalidomide  subsequent  to  thalidomide,  because  of 
disease progression, and 22 patients underwent ASCT.  The median age was 64 years (range 
male ratio of 18:29. The median residual-serum IgG-
ection was 3.2 g/L, IgA 0.3 g/L and IgM 0.2 g/L. Most patients suffered from recurrent 
moderate to severe bacterial infections, including the ASCT group. Fifteen patients suffered 
from different degrees of viral infections. 
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Multiple  myeloma  (MM)  is  associated  with  a  significant  risk  of  infection  due  to  immune 
dysfunction. Infections are a major cause of morbidity and mortality in MM patients. There 
are few data available regarding the prevalence of infection in MM patients, especially in 
conjunction with newer generations of immunomodulatory drugs (thalidomide, bortezomib, 
lenalidomide)  or  post  autologous  stem  cell  transplantation  (ASCT).  Intravenous 
immunoglobulin  (IVIG)  has  been  used  successfully  to  reduce  infection  rates  in the  stable 
We  retrospectively analyzed 47 patients with  MM  from March 2006 to June 2009  at our 
institution. All patients received thalidomide and steroid therapy for at least 6 months. Nine 
d  bortezomib  and  11  lenalidomide  subsequent  to  thalidomide,  because  of 
disease progression, and 22 patients underwent ASCT.  The median age was 64 years (range 
-level at time of 
ection was 3.2 g/L, IgA 0.3 g/L and IgM 0.2 g/L. Most patients suffered from recurrent 
moderate to severe bacterial infections, including the ASCT group. Fifteen patients suffered Medit J Hemat Infect Dis 2010; 2(1); Open Journal System 
All patients except 3 received IVIG therapy with a significant decline of the rate of infection 
thereafter  (p<001).  Our  analysis  shows  that  patients  with  MM  treated  with  the  new 
immunomodulatory drugs in conjunction with steroids are at significant increased risk of 
infection. Employing IVIG therapy appears to be an effective strategy to prevent infection in 
this cohort of patients. Further studies to confirm these findings are warranted. 
Introduction:  Multiple  myeloma  (MM)  is  a 
malignant  tumor  of  plasma  cells  associated  with 
impaired function  of  immunoglobulins,  which are 
an  essential  component  of  the  immune  system.
1,2
Patients with MM are at increased risk of infection, 
due to a combination of several factors, including 
immunoparesis and physical factors.
2,3
MM and chronic lymphocytic leukemia patients 
have been shown to have a 15-fold increased rate of 
infection  compared  to  age-matched  patients.
4,5
Infection is a major cause of death in MM patients, 
with  18-33%  of  serious  infections  resulting  in 
death.
4,5 The  types  of  infections  that  affect  MM 
patients  are  predominantly  bacterial,  affecting the 
respiratory  and  urinary  tracts  as  well  as  causing 
septicemia.
1-5 Furthermore,  patients  with  MM 
undergoing  stem cell  transplantation  are  at 
additional  risk  of  viral  reactivation  as  well  as 
opportunistic bacterial infections.
5,6
MM patients with hypogammaglobulinemia and 
those  who  have  been  actively  treated  with 
chemotherapy  are  at  high  risk  of  bacterial 
infection.
7,8 Furthermore,  MM  patients  are  also 
susceptible  to  systemic  and  localized  viral 
infections.
9 Due to the high rate of disease relapse, 
many  serious  infections  present  after  the  initial 
period  of  chemotherapy.
8.10  There  are  some  data 
suggesting  that  the  use of  intravenous 
immunoglobulins (IVIG) during the stable phase of 
MM disease can reduce infection rates and improve 
outcomes;
11  however,  there  is  a  lack  of  data 
regarding their use in other disease stages. 
IVIG  therapy  is  employed  mainly  in  the 
management of  immunocompromised  patients  to 
avoid recurrent infections.
11-13 
To date, there is only limited availability of data 
regarding the effect of ASCT in conjunction with 
new  immunomodulatory  drugs  (thalidomide, 
lenalidomide, bortezomib) on the rate of infection 
in MM patients. This study provides a retrospective 
analysis  of  the  infection  risk  and  outcomes  for 
patients  with  MM  who  underwent  ASCT  and/or 
received  these  new  drugs  for  immunomodulatory 
therapy.  Furthermore,  we  aimed  to  evaluate  the 
effect of IVIG therapy on the rate of infection in 
this cohort of patients. 
Patients and Methods: This study was conducted 
at  the  Launceston  General  Hospital,  a  tertiary 
referral centre for Northern Tasmania, Australia. All 
patients who presented for treatment of MM during 
the period between March 2006 and June 2009 were 
included in the study. The Statewide Human Ethics 
Committee of  Tasmania  approved  this study. The 
World  Health  Organization  criteria  were  used for 
the diagnosis of MM.
14 All patients had advanced 
disease and  were  undergoing  active  treatment  for 
MM. 
There were 47 patients with a median age of 64 
years (range 37-86) and a female to male ratio of 
29:18 (Table 1). There were 19 patients below 60 
years of  age and  28  patients above 60  years old. 
Most  of  the  patients  had  IgG  MM  (34  patients), 
while  4  patients  had  IgA  myeloma,  and  the 
remainder (9 patients) had Bence-Jones myeloma. 
Elevated serum free light chains were present in 25 
cases. Serum free light chains were measured using 
FREELITE  Human  Kappa  and  Lambda  Free  kits 
(The  Binding  Site,  San  Diego,  CA)  on  a  Dade 
Behring  nephelometer.  The  paraprotein  levels  at 
diagnosis  were  assessed,  as  well  as  the  levels  of 
residual  IgG,  IgA  and  IgM.  Immunoparesis  was 
defined  as  non-paraprotein  immunoglobulin 
concentrations below the laboratory lower limit of 
normal  (IgG  <7.5  g/L,  IgA  <0.8  g/L,  IgM  <  0.5 
g/L). There were 22 patients overall who underwent 
autologous stem cell transplantation (ASCT); 19 as 
upfront  treatment  and  3  as  salvage  therapy  for 
relapsed disease. 
The rate of recurrence and severity of infection 
was  recorded  for  all  patients.  An  acute  upper 
respiratory  tract  infection  (URTI)  was  defined  as 
the  recent  onset  of  rhinorrhea,  nasal  or  sinus 
congestion, otitis media,  pharyngitis and/or cough 
with clear chest radiograph, and a lower respiratory 
tract infection (LRTI) included patients with signs 
and/or  symptoms  of  pneumonia  and  a  new 
radiographic infiltrate (Table 2). 
Each infection was classified as bacterial, viral, 
fungal  or  unknown,  according  to  clinical, 
radiological  and  laboratory  findings.  Infections 
were further divided according to severity: severe 
infections  defined  as  serious  infections  requiring 
hospitalization  and  intravenous 
antibiotics/antifungals  and/or  antivirals,  or  whenMedit J Hemat Infect Dis 2010; 2(1); Open Journal System 
Table 1: Patient characteristics. 
IVIG=intravenous immunoglobulin.
life-threatening  complications  occurred  including 
septicemia,  pneumonia,  or  ICU  admission; 
moderate  infections  were  secondary  bacterial 
infections of  the  upper  or  lower  respiratory  tract, 
urinary tract, skin abscesses, cellulitis or localized 
herpes  zoster  that  may  have  also  required 
hospitalization  and  intravenous  
antibiotics/antivirals;  minor/mild  infections  were 
those  requiring  only  oral  antimicrobials  without 
hospitalization.  Microbiological  tests  were 
performed  at  the  Department  of Microbiology, 
Launceston General Hospital. 
IVIG  is  derived  from  the  plasma  of  blood 
donors  and  consists  mainly  of  pooled 
immunoglobulin  G (IgG) with  a small amount  of 
immunoglobulin  A  (IgA)  in  a  maltose  solution 
(Commonwealth Serum Laboratories, Australia).
Of the 47 patients with MM in this study, 44 
patients  received  monthly  infusions  of  IVIG  at 
0.25-0.4 g/kg body weight (median 24 g; range 12-
48 g). Three patients with mild or minor infections 
and normal IgG levels did not receive any infusions. 
The patients received monthly IVIG as outpatients 
and tolerated the therapy well without side effects. 
Results: The 47 patients included in this study were 
first diagnosed with  MM between the years 2000 
and  2008.  At  the  time  of  diagnosis,  the  median 
paraprotein  level  was  32  g/L  (range  15–102), 
excluding patients with Bence-Jones myeloma who 
did not have a measureable paraprotein level. The 
median residual IgG level at time of infection was 
3.2 g/L (range 0.3–11.0), median IgA 0.3 g/L (range 
0.1–4, excluding patients with IgA myeloma), and 
median IgM 0.2 g/L (range 0.1–1.1). Each median 
is below the normal reference range as determined 
by our laboratory, which is 7.5-15.6 g/L for IgG, 
0.8-4.5 g/L for IgA and 0.5-2.6 g/L for IgM. The 
median neutrophil count at the time of infection was 
measured  at  3.4/nL  (range  1.5  -15.9),  with  the 
Total number of patients  47
Sex
   Male
   Female
29
18
Age
   <60
   >60
Median 64 (range 37-86) years
19
28
Disease Type
   IgG
   IgA
   Bence Jones myeloma
  Concomitant positive free light chains
34
4
9
25
Median paraprotein level at diagnosis
Median residual IgG level at time of infection 
Median IgA level at the time of infection 
Median IgM Level at the time of infection 
Median neutrophil count at the time of infection
Median lymphocyte count at the time of infection
32 (range 14.9-102) g/L
3.2 (range 0.3-11) g/L
0.3 (range 0.1-4) g/L
0.2 (range 0.1-1.1) g/L
3.4 (range 1.5-15.9)/nL
1.7 (range 0.3-5.1)/nL
Mean serum free kappa light chain
Mean serum free lambda light chain 
523 mg/L
697 mg/L
Treatment received:
ASCT (upfront)
ASCT (relapsed)
Thalidomide 
Bortezomib
Lenalidomide
19 
3
47
9
11
Disease status during occurrence of infection
Consolidation /maintenance therapy 
Treatment for relapsed disease 
Induction therapy 
24
20
3
Total IVIG dose (0.25-0.4g/kg body weight) 24 g (range 12-48)
Patients receiving steroids:
  Dexamethasone
  Prednisolone
23
24Medit J Hemat Infect Dis 2010; 2(1); Open Journal System 
Table 2: Summary of infections and outcome in patients who were actively treated for multiple myeloma. URTI=upper respiratory 
tract  infection,  LRTI=lower  respiratory  tract  infection,  GITI=gastro  intestinal  tract  infection;  UTI=urinary  tract  infection,
ICU=Intensive Care Unit, IVIG=immunoglobulin therapy. 
Types of infection 
   
   URTI (recurrent)
   LRTI (recurrent)
   GITI
Septicemia 
UTI
Oral Candida infection
Cholecystitis
Viral infection 
Localized herpes infection 
Generalized varicella zoster infection
prior to IVIG therapy
40
36
3
3
8
2
1
19
4
after to IVIG therapy
10
6
0
0
0
0
0
2
0
Length of admission for infection Median 12 days (range 1-35) Median 3 days (range 1-7)
ICU admission  Three patients required ventilation for 
severe pneumonia
One  patient  admitted  to  ICU 
for multiorgan failure*
Degree of bacterial infection   
Severe
Moderate
Mild or minor
Concomitant history of viral infection
8/47 (17%)
26/47 (55%)
13/47 (28%)
23/47 (48%)
0* 
16/47 (34%) 
10/47 (21%)
2/47 (4%) 
Rate of infection in the ASCT group 
Moderate-severe bacterial infection 
Mild-moderate bacterial infection 
Viral infection
Median onset of all infections post transplant
11/22 (50%)
11/22 (50%) 
10/22 (48%)
12 months (range 2-20)
Median residual IgG level after IVIG therapy
Median residual IgA level after IVIG therapy
Median residual IgM level after IVIG therapy
5.5 (range 1.2-16.2) g/L
0.4 (range 0.1 -3.7) g/L
0.3 (range 0.1-1.0) g/L
Median length of follow up for MM disease
Median length of follow up after IVIG 
36 months (range 8-106)
10 months (6-33)
Outcome of the disease
Complete remission (CR)
Near CR 
Partial remission
Stable disease 
Progressive disease 
Deceased due to disease progression 
2
9
22
2
5
7 (2* with concomitant infection) 
*Two patients developed pneumonia when they presented in terminal disease progression with severe pancytopenia (neutrophils 
<0.5/nl) and multiorgan failure with almost complete bone marrow replacement by plasma cells. These patients were not considered 
as infection secondary to hypogammaglobulinemia. 
normal neutrophil range being 2.0-7.5/nL of the 47 
patients, 17 patients were positive for Bence-Jones 
proteinuria,  including  the  9  patients  with  Bence-
Jones  myeloma.  Throughout  the  course  of  their 
disease,  25 patients had  elevated serum free light 
chains with a mean peak level of free kappa of 523 
mg/L and free lambda of 697 mg/L.  All 47 patients 
were actively treated with thalidomide for at least 6 
months, and all received different doses of steroids 
during  their  course  of  treatment,  when  the 
infections  occurred.  Subsequently,  nine  patients 
received bortezomib and 11 received lenalidomide 
for  relapsed  or  progressive  disease.  Thirty-three 
patients  were  at  high  risk  of  developing 
Pneumocystis jirovecii pneumonia due to prolonged 
treatment with  intermediate- to  high-dose  steroids 
(40 mg oral dexamethasone for 4 consecutive days, 
3  times  monthly)  and  therefore  received 
standardized  trimethoprim  and  sulfamethoxazole 
prophylaxis.  Prophylactic  antiviral  treatment  with 
famcyclovir  was  started  for  23  patients  with  a 
history  of  herpes  simplex  and/or  varicella  zoster 
virus (VZV) reactivation. Prior to IVIG therapy, 4 
patients developed generalized VZV infection and 
received  IV  acyclovir  for  10  days  followed  by 
maintenance famciclovir orally. Localized recurrent 
herpes zoster infection was noted in 11 patients and 
required  ongoing  antiviral  treatment.  After  IVIG Medit J Hemat Infect Dis 2010; 2(1); Open Journal System 
therapy,  there  were  no  recorded  admissions  for 
patients with  either  generalized  or  localized  VZV 
infections.  However,  these  patients  were 
commenced  on  concomitant  antiviral  prophylaxis 
after the occurrence of these infections. 
Prior to the introduction of IVIG therapy, most 
of the patients were admitted to hospital for a period 
extending from a few days to several weeks with 
various types of infection that required intravenous 
antibiotic or antiviral therapy. The median length of 
stay was 12 days (range 1-35 days). Five patients 
presented  with  mild  infection  that  required  oral 
antibiotics only. There were 26 patients assessed as 
having  mild  to  moderate  infection  that  required 
antibiotics, while 8 patients experienced moderate 
to severe infection that required hospitalization and 
intravenous antibiotics and antifungals, 3 of these 
required additional ICU support. Furthermore, the 
patients who  developed  severe  infection requiring 
ICU admission had undergone ASCT and were in 
the  first  12  months  post  transplant.  Most  of  the 
patients  suffered  from  URTI  (40  patients)  and/or 
LRTI (36 patients), while 8 patients complained of 
recurrent urinary tract infections (UTI). Most of the 
cases of mild to moderate infections required oral 
antibiotics, with complete resolution of the infection 
thereafter.  There  were  3  cases  diagnosed  with 
septicemia;  the  organisms  were  Staphylococcus
species  (2  patients)  and  Enterococcus species  (1 
patient).  Central  intravenous  lines  were  inserted 
after the occurrence of infections in 6 patients who 
had poor  venous  access, in  order  to  facilitate  the 
regular use of IVIG therapy. These lines have not 
been  associated  with  any  recorded  case  of 
septicemia  to  date,  based  on  blood  cultures 
withdrawn  from these  catheters.  All  patients  who 
underwent  ASCT  experienced  mild  to  severe 
bacterial infections and suffered at some stage from 
LRTI  prior  to  IVIG  therapy.  Furthermore,  10 
patients in the ASCT group developed localized (6 
patients)  or  generalized  (4  patients)  herpes  zoster 
infections prior to IVIG therapy at a variable time 
of onset after transplant, with a median onset of 16 
months (range 6-20). Median onset of all infections 
(bacterial  and  viral)  in  the  ASCT  group  was  12 
months  post-transplant  (range  2-20).  Following 
IVIG therapy, the median residual IgG level among 
the patients significantly improved to 5.5 g/L (range 
1.2-16.2)  (p=0.03),  while  the  median  paraprotein 
level after myeloma treatment decreased  to 8 g/L 
(0-47). 
We  observed  that  MM  patients  who  received 
IVIG  therapy  did  not  have  recorded  hospital 
admissions  for  severe  infection  after 
commencement  of  the  IVIG,  with  a  median 
observed  interval  post  commencement  of  IVIG 
therapy of 10 months (range 6-33). However, mild-
moderate  infections  were  observed  in  16  patients 
who  developed  URTI  (10)  and  LRTI  (6)  that 
required intravenous antibiotics and hospitalization 
with successful control of their infections. The risk 
of bacterial and viral infection was greatly lowered 
after IVIG therapy, with a risk ratio of 0.13 (95% 
CI  0.09  to  0.19;  p<0.001)  estimated  by  Poisson 
regression.
Among the patients who received IVIG therapy, 
33 were in remission, 2 had stable disease and 12 
had progressive disease. Most of the patients (43) 
received  concomitant  monthly  intravenous 
bisphosphonate  therapy  during  administration  of 
IVIG. All patients who received IVIG were actively 
treated for myeloma disease with either one of the 
immunomodulating  agents  (thalidomide, 
bortezomib, lenalidomide) at the time of infection. 
There were 24 patients in consolidation on therapy 
with thalidomide, while 20 patienst were treated for 
disease  progression  with  bortezomib  and 
lenalidomide  and  three  patients  were  treated  by 
induction  treatment  for  myeloma  disease  with 
thalidomide  and  dexamethasone.  After  a  median 
follow-up of 36 months (range 8-106), 40 patients 
were  alive  (86%),  2  of  these  were  in  complete 
remission,  9  in  near-complete  remission,  22  in 
partial remission, 2 with stable disease and 5 with 
progressive  disease.  Seven  patients  succumbed  to 
their  primary  disease;  two  transformed  to  plasma 
cell leukemia and died as a consequence of disease 
progression,  two  developed  multi-organ  failure 
including respiratory and renal failure that required 
hospitalization  with  associated  chest  infection, 
while 3 died from cardio-respiratory failure during 
disease progression at home. 
Discussion: In the new era of immunomodulatory 
therapy  for  MM,  employing  thalidomide, 
bortezomib and lenalidomide, there is an additional 
modification of the immune response of the hosts. 
There is an increased risk of viral infection in MM 
patients who are receiving bortezomib.
9 Other data 
suggest  that  thalidomide  has  an  effect  on  T-cells 
and  is  associated  with  opportunistic  infections.
15
Thalidomide is an antiangiogenic agent that inhibits 
the production of interleukin (IL)-6 and activates T 
cells to produce IL-2 which alters the number and 
function  of  natural  killer  cells.
15,16  Furthermore, 
thalidomide  has  been  shown  to  have  anti-tumor 
necrosis  factor  alpha  (TNF-α)  effects,  which 
increases  the  risk  of  opportunistic  infection.
15Medit J Hemat Infect Dis 2010; 2(1); Open Journal System 
Lenalidomide is an immunomodulating drug of the 
IMiDs  class  which  has  a  similar  mechanism  of 
action  to  thalidomide.  The  drug  has  a  different 
toxicity  profile  that  includes  neutropenia,  an 
additional  risk  factor  for  infection.
17-19
Lenalidomide also shows anti-inflammatory effects, 
with  downregulation  of  TNF-α  and  pro-
inflammatory  cytokine  production.
20,21 A  recent 
safety study of lenalidomide as a single agent in the 
treatment  of  MM  recorded  60%  grade  3-4 
neutropenia with only 4% of patients suffering from 
severe  infections.
19    The  cumulative  effect  of 
addition  of  dexamethasone  therapy  reportedly 
increases  the  risk  of  infection  to  11.3%  using 
lenalidomide  plus  dexamethasone  versus  6.2%  in 
the  dexamethasone  alone  treated  group.
22  
Bortezomib  is  a  proteasome  inhibitor  with  an 
inhibitory  effect  on  T  cell  proliferation.
18,23 The 
possible  effect  of  bortezomib  on  cell-mediated 
immunity  is  likely  responsible  for  the  increased 
incidence of herpes zoster infections found in MM 
patients.
9  
In our series, 47 patients with MM were treated 
with  thalidomide  in  addition  to  steroids.  The 
steroids  were  used  concomitantly  to  the 
immunomodulatory  therapy  to  increase  the 
synergistic  effect.
16-18,22,23    Patients  received 
dexamethasone  doses  between  20  mg  and  40  mg 
orally 1-2 weekly for at least 6 months (23 patients) 
or  prednisolone  25  mg  orally  daily  or  every 
alternate day (24 patients) for at least a period of 6 
months,  concomitantly  to  the  immunomodulatory 
drugs.  Prior  to  IVIG  therapy,  42  MM  patients, 
including the ASCT group, suffered from different 
degrees of mild to moderate infections (55%), and 
moderate to severe infections (17%) (Table 2). The 
relatively high  incidence  of  infection  rates in  our 
study are mainly due to the facts that we registered 
all occurrence of mild and moderate infections and 
also included  the  ASCT  group  in  the  analysis  as 
well  as  relapsed  patients  who  were  receiving 
different immunomodulatory agents. There was no 
significant difference in the prevalence of infections 
in  patients  treated  with  thalidomide  compared  to 
lenalidomide or bortezomib. It is worth noting that 
the  residual  normal  IgG  levels  improved 
significantly (p=0.03), with further improvement of 
IgA and IgM levels, after IVIG therapy. However, 
the low levels of IgG remained the surrogate marker 
for  immunodeficiency  and  susceptibility  for 
infections.    The  rate  and  severity  of  infections, 
hospital  admission  and  use  of  intravenous 
antibiotics/antivirals  were  reduced  significantly 
after  commencement  of  monthly  IVIG  therapy 
(p<0.001).  Our results  are largely in  concordance 
with a meta-analysis of 6 different randomised trials 
studying  the  effect  of  IVIG  therapy  in  different 
patient  populations  with  CLL  and  MM,  which 
showed  no  survival  benefit,  but  there  was  a 
significant decrease in the occurrence of major and 
clinically  documented  infections.
24 However,  the 
patients populations and therapy received in these 
studies are different from our series.
Conclusions: In  summary,  our  data  suggest  that 
IVIG  therapy  may  play  an  important  role  in  the 
supportive management during the active treatment 
of  MM  patients,  especially  those  receiving  new 
immunomodulatory agents or ASCT. Accordingly, 
there was a significant benefit of IVIG therapy in 
MM  patients  with  a  corresponding  decrease  in 
hospital admission for recurrent infections or use of 
intravenous  antibiotic  and  or  antiviral  therapy.  
Further  trials  studying  the  effect  of  IVIG  in  this 
cohort of patients are warranted. 
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